TY  - JOUR
T1  - Effects of Lipid Profiles and Vitamin D Levels on the Degree of Fatty Liver in Children with Non-Alcoholic Fatty Liver Disease
TT  - Non-Alkolik Yağlı Karaciğer Hastalığı Olan Çocuklarda Lipid Profilleri ve D Vitamini Düzeylerinin Yağlı Karaciğer Derecesi Üzerindeki Etkileri
AU  - Gülseren, Arzu
AU  - Gulcu Taskin, Didem
PY  - 2025
DA  - August
Y2  - 2025
DO  - 10.29058/mjwbs.1591828
JF  - Medical Journal of Western Black Sea
JO  - Med J West Black Sea
PB  - Zonguldak Bulent Ecevit University
WT  - DergiPark
SN  - 2822-4302
SP  - 181
EP  - 186
VL  - 9
IS  - 2
LA  - en
AB  - Aim: The aim of the study was to compare vitamin D, triglyceride and cholesterol levels of hepatosteatosis patients with healthy controlpatients.Material and Methods: Ninety-nine patients with hepatosteatosis and healthy control patients were included in our study retrospectively.The patients included in the study were patients who applied to the pediatric gastroenterology outpatient clinic between 2020 and 2023.Results: A total of 99 patients, 47 (47.5%) with hepatosteatosis and 52 (52.5%) in the control group, were included in our study. Mean ALTvalues were 35.2 ± 19.5 and 28.3 ± 13.0 in the hepatosteatosis and control groups, respectively (P= 0.039). Mean triglyceride (136 ± 28 vs125 ± 24; P= 0.042) and cholesterol (165 ± 20 vs 154 ± 20; P= 0.010) levels were higher in the hepatosteatosis group than in the controlgroup and the result was found to be significantly different. Mean vitamin D levels did not differ between the groups. Vitamin D deficiency wasfound to be high in both groups, but no difference was analyzed between the groups (72.3% vs 61.5%; P= 0.491).Conclusion: Triglyceride and cholesterol levels were found to be higher in patients with hepatosteatosis. Fasting blood glucose is higher inthe hepatosteatosis group. Based on these results and the literature, patients with hepatosteatosis pose a risk for important diseases suchas metabolic syndrome and cardiovascular diseases such as atherosclerosis in the following years.
KW  - Cholesterol
KW  - hepatosteatosis
KW  - triglyceride
KW  - vitamin D
N2  - Amaç: Çalışmanın amacı hepatosteatoz hastalarının D vitamini, trigliserit ve kolesterol düzeylerini sağlıklı kontrol hastalarıyla karşılaştırmaktır.Gereç ve Yöntemler: Çalışmamıza retrospektif olarak hepatosteatozlu 99 hasta ve sağlıklı kontrol hastaları dahil edildi. Çalışmaya dahiledilen hastalar 2020-2023 yılları arasında çocuk gastroenteroloji polikliniğine başvuran hastalardı.Bulgular: Çalışmamıza hepatosteatozlu 47 (%47,5) ve kontrol grubunda 52 (%52,5) olmak üzere toplam 99 hasta dahil edildi. Ortalama ALTdeğerleri hepatosteatoz ve kontrol gruplarında sırasıyla 35,2 ± 19,5 ve 28,3 ± 13,0 idi (P= 0,039). Ortalama trigliserit (136 ± 28 vs 125 ± 24;P= 0.042) ve kolesterol (165 ± 20 vs 154 ± 20; P= 0.010) düzeyleri hepatosteatoz grubunda kontrol grubuna göre daha yüksekti ve sonuçanlamlı olarak farklı bulundu. Ortalama D vitamini düzeyleri gruplar arasında farklılık göstermedi. Her iki grupta da D vitamini eksikliği yüksekbulundu, ancak gruplar arasında fark analiz edilmedi (%72.3 vs %61.5; P= 0.491).Sonuç: Hepatosteatozlu hastalarda trigliserit ve kolesterol düzeyleri daha yüksek bulundu. Açlık kan şekeri hepatosteatoz grubundadaha yüksektir. Bu sonuçlara ve literatüre dayanarak, hepatosteatozlu hastalar ilerleyen yıllarda metabolik sendrom ve ateroskleroz gibikardiyovasküler hastalıklar gibi önemli hastalıklar için risk oluşturmaktadır.
CR  - 1. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk
S, Benson JT, Enders FB, Angulo P. The natural history
of non-alcoholic fatty liver disease in children: a follow-up
study for up to 20 years. Gut. 2009 Nov;58(11):1538-44.
CR  - 2. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR,
Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram
SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline
for the Diagnosis and Treatment of Nonalcoholic Fatty
Liver Disease in Children: Recommendations from the Expert
Committee on NAFLD (ECON) and the North American
Society of Pediatric Gastroenterology, Hepatology and
Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017
Feb;64(2):319-334.
CR  - 3. Sezer OB, Buluş D, Hızlı Ş, Andıran N, Yılmaz D, Ramadan
SU. Low 25-hydroxyvitamin D level is not an independent
risk factor for hepatosteatosis in obese children. J Pediatr
Endocrinol Metab. 2016 Jul 1;29(7):783-8.
CR  - 4. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/
non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis
and clinical course. Best Pract Res Clin Gastroenterol.
2004 Dec;18(6):1089-104.
CR  - 5. Kitson MT, Roberts SK. D-livering the message: The importance
of vitamin D status in chronic liver disease. J Hepatol
2012;57:897–909.
CR  - 6. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM,
Gamble GD, Reid IR. The effects of seasonal variation of
25-hydroxyvitamin D and fat mass on a diagnosis of vitamin
D sufficiency. Am J Clin Nutr. 2007 Oct;86(4):959-64.
CR  - 7. Deurenberg P, Weststrate JA, Seidell JC. Body mass index
as a measure of body fatness: age- and sex-specific prediction
formulas. Br J Nutr. 1991 Mar;65(2):105-14.
CR  - 8. Holick MF. Vitamin D deficiency. N Engl J Med
2007;357:266–81.
CR  - 9. Candace Y. Parker-Autry, Kathryn L. Burgio, and Holly E.
Richter. Vitamin D Status – A Clinical Review with Implications
for the Pelvic Floor. Int Urogynecol J. 2012; 23(11):
1517–1526.
CR  - 10. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty
liver disease. World J Gastroenterol 2014;20:7392.
CR  - 11. Korkmaz HA, Arya VB, Barisik V, Atila D, Coskunol F, Alci
S, Cekdemir YE, Torlak D, Özkan B. The Association between
Vitamin D Deficiency and Hepatosteatosis in Children
and Adolescents with Obesity. Horm Res Paediatr.
2024;97(4):326-333.
CR  - 12. Yildiz I, Erol OB, Toprak S, Cantez MS, Omer B, Kilic A,
Oguz F, Uysalol M, Yekeler E, Unuvar E. Role of vitamin
D in children with hepatosteatosis. J Pediatr Gastroenterol
Nutr. 2014 Jul;59(1):106-11.
CR  - 13. Dursun F, Gerenli N, Dur SMS, Kirmizibekmez H. The relationship
between vitamin D level and hepatosteatosis in
obese children. North Clin Istanb. 2018 Aug 8;6(1):28-32.
CR  - 14. Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D
and the vitamin D receptor in liver pathophysiology. Clin
Res Hepatol Gastroenterol 2011;35:295–302.
CR  - 15. Basarir G, Ozcabi B, Aksu Sayman O, Ozturkmen Akay H,
Yildiz FM. Evaluation of clinical, endocrine and metabolic
findings in obese children with and without hepatosteatosis.
J Pediatr Endocrinol Metab. 2021;34(9):1081-1087.
CR  - 16. Aslan A, Erdemli S, Günaydın GD, Aslan M, Yazar RÖ,
Kabaalioğlu A, Ağırbaşlı MA. Cardiometabolic risk factors
in Turkish children with hepatosteatosis. Turk J Pediatr.
2019;61(5):714-722.
CR  - 17. Lu CW, Lin MS, Lin YS, Chang IJ, Tsai MH, Wei KL, Chen
MY. Aminotransferase Ratio Is a Useful Index for Hepatosteatosis
in Children and Adolescents: A Cross-Sectional
Observational Study. Gastroenterol Nurs. 2019;42(6):486-
495.
CR  - 18. Agirbasli M, Cakir S, Ozme S, Ciliv G. Metabolic syndrome
in Turkish children and adolescents. Metabolism 2006; 55:
1002-1006.
UR  - https://doi.org/10.29058/mjwbs.1591828
L1  - https://dergipark.org.tr/en/download/article-file/4396093
ER  -